Maybe there is a glimmer of hope that Origin will make a rival bid out of left field for ESG........who would have thought that Lyon would be scooped up by the Dockers.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
